Cediranib is a potent ATP-competitive inhibitor against VEGFR2 with additional activity against PDGFRβ and c-Kit.45 Experimentally, cediranib not only prevented new vessel formation, but also induced vascular regression in xenograft tumor models. The gene discussed is KDR; the disease is neoplasm.